Compare Citius Pharmaceuticals Inc (CTXR) vs SoundHound AI Inc (SOUN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs SoundHound AI Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while SoundHound AI Inc trades at $5.39 (market cap $2.45B). The key difference: SoundHound AI Inc is far larger — about 179.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 16,881,989). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and SoundHound AI Inc for 23 Days on average.
| CTXR | SOUN | |
|---|---|---|
Market Cap | $13.62M | $2.45B |
Volume | 132,438 | 16,881,989 |
Sector | Health | Technology |
52-Week High | $1.82 | $21.40 |
52-Week Low | $0.48 | $5.52 |
Typical Hold Time | 17 Days | 23 Days |
Enterprise Value | $3.79M | $2.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% with a bearish technical signal despite oversold RSI readings. The company shows early commercial progress with $7.1M revenue in fiscal 2026 from LYMPHIR sales, though profitability remains challenged with negative margins and significant cash burn. Analyst consensus is strongly bullish with 83% buy ratings and a $5.00 price target, reflecting optimism about the oncology drug pipeline.
Investment outlook balances high-risk biotech potential against substantial financial challenges. The primary opportunity lies in LYMPHIR's commercial ramp-up and market adoption, while risks include continued cash burn, execution hurdles, and the speculative nature of early-stage biopharmaceutical development.
SoundHound AI (SOUN) trades at $5.52, down 1.95% amid bearish technical signals despite recent earnings beats. The company shows strong revenue growth with 2025 revenue of $168.92M and projected 2026 revenue of $203M, but faces significant profitability challenges with a -67.45% net income margin. Recent developments include expansion into banking AI agents and the OASYS Edge embedded architecture launch for vehicles and smart devices.
While analyst consensus remains bullish with a $9.33 price target (75% buy ratings), the stock faces headwinds from persistent losses, negative cash flow projections for 2026, and insider selling activity. The key investment thesis hinges on voice AI adoption growth versus the company's ability to achieve profitability amid high valuation multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About SoundHound AI Inc
SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →
